The marijuana industry has been high on analysts' lists ever since Justin Trudeau and the Liberal Party were elected in late 2015. Some analysts predict the legalized pot industry to be a $5 billion market in Canada alone (http://business.financialpost.com/news/agriculture/canadian-marijuana-stocks-jump-as-liberal-wins-signals-legalization-on-the-table). Thus, it is clear that a new and lucrative market is burgeoning.
Analysts are predicting a high level of M&A activity in this space. The industry is currently comprised of many small players, which makes it attractive for bigger and more established corporations. Todd Hagopian, an analyst operating a market fund focused on the biotech industry, is predicting that big pharmaceutical corporations will likely become acquirers in the near future. His thinking is that they are cash heavy and are looking for new ways to continue growing (http://www.forbes.com/sites/kenkam/2016/07/26/six-major-biotech-acquisitions-you-could-see-in-2016-part-3/#303cb98c1686). Moreover, M&A activity has already begun picking up momentum. Data from Virdian Capital and Research, an index focused on the Cannabis industry, shows that 33 acquisitions were conducted in 2014. The president of the index, Scott Greiper, expects this acquisition activity to continue to grow into the foreseeable future.
It is true that the industry is not all green grass. There are a few weeds that need to be pulled out before it can flourish into its full potential; one such obstacle is full legalization, or at least an established and stable regulatory framework. The recently announced new set of regulations for accessing medicinal marijuana in Canada, the Access to Cannabis for Medical Purposes Regulations (ACMPR), may be seen as another stepping stone in that direction, as the ACMPR will replace the existing Marijuana for Medical Purposes Regulations (MMPR). These new regulations, while an interim measure, are intended to expand patients' limited access to marijuana under the old regulations and may also be seen as an endorsement of the system of "licensed producers" that has developed under the MMPR, as licensed producers will continue to be exclusive large-scale producers of cannabis under the ACMPR. The ACMPR may therefore provide some comfort to industry players that regulated medicinal marijuana is here to stay. See http://news.gc.ca/web/article-en.do?nid=1110389.
The author would like to thank Fahad Diwan, Summer Student, for his assistance in researching and preparing this legal update.
About Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.
Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.
For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.
Law around the world
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.